Two teenagers from British Columbia have become the first in Canada to receive a newly approved treatment that can delay the progression of Type 1 diabetes. The treatment, called teplizumab, was recently greenlit by Health Canada and is now being administered at B.C. Children's Hospital in Vancouver.
Life-Changing Treatment for Young Patients
Jack Thiessen, a 16-year-old from Prince George, is one of the two youths who underwent the 14-day intravenous infusion therapy. Jack, who loves outdoor activities such as hiking, fishing, and camping, was concerned about how diabetes would impact his lifestyle. His younger brother and father both have Type 1 diabetes, so the family is well-acquainted with the challenges of managing the condition.
Jack had been participating in a trial monitoring youth with siblings who have Type 1 diabetes. When his blood sugar levels began to fluctuate, indicating he was likely to progress to Stage 3 of the disease, he became an ideal candidate for the new treatment.
How Teplizumab Works
Teplizumab is an immunotherapy drug that targets the immune system in patients with early-stage Type 1 diabetes. It slows the destruction of insulin-producing cells in the pancreas, thereby delaying the onset of the disease. While it is not a cure, it can postpone the need for insulin therapy and reduce the risk of severe complications, such as diabetic ketoacidosis (DKA).
Dr. Dina Panagiotopoulos, a pediatric endocrinologist at B.C. Children's Hospital, explained that managing Type 1 diabetes is extremely complex, especially during the teenage years. Delaying the progression of the disease can significantly reduce stress and improve quality of life for young patients.
Compassionate Grounds Funding
The treatment was provided on compassionate grounds, as teplizumab is not yet publicly funded. Access is currently restricted to patients identified through research studies. Jack and his family received support from Dr. Panagiotopoulos to secure funding for the therapy.
Jack reported no side effects from the treatment and described his experience at Ronald McDonald House and B.C. Children's Hospital as positive. He is now hopeful that his diabetes progression will be delayed, allowing him to continue enjoying his outdoor adventures without the constant worry of managing the disease.
Approximately 40 to 60 percent of children with Type 1 diabetes may develop DKA, a life-threatening condition characterized by severely high blood sugar, dehydration, breathing difficulties, and reduced consciousness. Teplizumab offers a promising option to reduce this risk and improve outcomes for young patients.
